New drugs in gastrointestinal oncology: Current status and future directions;Nouveaux agents de chimiotherapie en cancerologie digestive: Acquis et perspectives

Gastroenterologie Clinique et Biologique

Volumn 23, Issue 11, 1999, Pages 1145-1165

  Conroy, Thierry ^a   Paillot, Bernard ^b   Adenis, Antoine ^c  

^a CHU NANCY BRABOIS   (France)

^b HÔPITAL CHARLES NICOLLE   (France)

^c CENTRE OSCAR LAMBRET   (France)

Author keywords

Chemotherapy; Colorectal cancer; Gastrointestinal cancer; Gemcitabine; Irinotecan; Oxaliplatin; Raltitrexed; Taxane

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXIFLURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEMCITABINE; IRINOTECAN; NAVELBINE; NOLATREXED; OXALIPLATIN; PACLITAXEL; PEMETREXED; RALTITREXED; TEGAFUR; TOPOTECAN; TRIMETREXATE GLUCURONATE; UFT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; FLOXURIDINE; PLATINUM COMPLEX; QUINAZOLINE DERIVATIVE; TAXOID; THIOPHENE DERIVATIVE; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; ESOPHAGUS CANCER; HUMAN; MAJOR CLINICAL STUDY; NEUROTOXICITY; NEUTROPENIA; PANCREAS CANCER; REVIEW; STOMACH ADENOCARCINOMA; GASTROINTESTINAL TUMOR;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DEOXYCYTIDINE; FLOXURIDINE; GASTROINTESTINAL NEOPLASMS; HUMANS; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; QUINAZOLINES; TAXOIDS; TEGAFUR; THIOPHENES; VINBLASTINE;

EID: 0033405926     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (152)

1. Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, et al. Tomudex (ZD1694) : results of a randomized trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995;31A : 1945-54.
2. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, Van Hazel G, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 1998;16: 2943-52.
3. Padzur R, Vincent M for the Tomudex Colorectal Cancer Study Group. Raltitrexed (Tomudex®) versus 5-fluorouracil and leucovorin (5-FU+LV) in patients with advanced colorectal cancer (ACC) : results of a randomized, multicenter, North American trial (abstract). Proc Am Soc Clin Oncol 1997;16:228a.
4. Anderson H, Palmer MK. Measuring quality of life : impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials. Br J Cancer 1998;77, (Suppl 2) : 9-14.
5. Zalcberg J, Cunningham D, Rath U, Olver I, Kerr D, Van Cutsem E, et al. Modulated 5-FU : female gender and increasing age are associated with significantly more grade 3 ou 4 leucopenia and mucositis (abstract). Proc Am Soc Clin Oncol 1996;15:201.
6. Maughan TS, James RD, Kerr D, McArdle C, Ledermann JA, Seymour M, et al. Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (de Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 1999;18:262a.
7. Stephens RJ, Hopwood P, Johnston C, Maughan TS on behalf of the British MRC Colorectal Cancer Working Party. The value of quality of life (QL) outcomes in comparing 3 chemotherapy regimens (de Gramont, Lokich and Raltitrexed) in a multicentre randomised trial of metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 1999;18:575a.
8. Ross P, Heron J, Cunningham D. Cost of treating advanced colorectal cancer : a retrospective comparison of treatment regimens. Eur J Cancer 1996;32A (Suppl 5) : S13-7.
9. Farrugia DC, Norman AR, Cunningham D. Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex®) in advanced colorectal cancer. Eur J Cancer 1998;34:987-91.
10. Zalcberg J, Ibrahaim J, Johnston PG, Locker GY, O'Dwyer PJ, Weiner LM, et al. ECOG phase II study of Tomudex® in advanced colorectal cancer (abstract). Proc Am Soc Clin Oncol 1997;16: 268a.
11. Köhne CH, Thuss-Patience P, Friedrich M, Daniel PT, Kretzschmar A, Benter T, et al. Raltitrexed (Tomudex) : an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br J Cancer 1998;77 (Suppl 6) : 973-7.
12. Meropol NJ, Pazdur R, Vincent M, Willson JKV, Kelsen DP, Douglass HO Jr. Phase II study of ZD1694 in patients with advanced gastric cancer. Am J Clin Oncol 1996;19:628-30.
13. Pazdur R, Meropol NJ, Casper ES, Fuchs C, Douglass HO, Vincent M, et al. Phase II study of ZD1694 (Tomudex®) in patients with advanced pancreatic cancer. Invest New Drugs 1995;13:355-8.
14. Rougier P, Ducreux M, Kerr D, Carr BI, Francois E, Adenis A, et al. A phase II study of raltitrexed ('Tomudex') in patients with hepatocellular carcinoma. Ann Oncol 1997;8:500-2.
15. Belani CP, Lembersky B, Ramanathan R, Cohn A, Loh K, Miller W, et al. A phase II trial of Thymitaq™ (AG337) in patients with adenocarcinoma of the colon (abstract). Proc Am Soc Clin Oncol 1997;16:272a.
16. Loh K, Stuart K, Cohn A, White C, Hines J, Miller W, et al. A phase II trial of Thymitaq ™ (AG337) in patients with adenocarcinoma of the pancreas (abstract). Proc Am Soc Clin Oncol 1997;16:265a.
17. Mani S, Rosen L, Bennett P, Dancey J, Conner S, Johnston A, et al. A phase II trial of nolatrexed dihydrochloride (Thymitaq. AG337) in patients with advanced hepatocellular carcinoma (HCC). Ann Oncol 1998;9 (Suppl 2) : 162.
18. Mok T, Liu M, Lee SD, Chao Y, Leung T, Johnston A, et al. A phase II/III randomized study comparing efficacy of nolatrexed (Thymitaq, AG337) to doxorubicin in patients with unresectable hepatocellular carcinoma (HCC). Ann Oncol 1998;9 (Suppl 2) : 173.
19. Calvert AH, Walling JM. Clinical studies with MTA. Br J Cancer 1998;78 (Suppl 3) : 33-40.
20. Blanke CD, Messenger M, Taplin SC. Trimetrexate : review and current clinical experience in advanced colorectal cancer. Semin Oncol 1997;24 (Suppl 18) : 57-63.
21. Haller DG. Trimetrexate : experience with solid tumors. Semin Oncol 1997;24 (Suppl 18) : 71-8.
22. Levi F, Misset JL, Brienza S, Adam R, Metzger G. Itzakhi M, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992;69:893-900.
23. Extra JM, Marty M, Brienza S, Missel JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998;25 (Suppl 5) : 13-22.
24. Gilles-Amar Y, Garcia ML, Sebille A, Maindrault-Goebel F, Louvet C, Beerblock K, et al. Evolution of severe sensory neuropathy with oxaliplatin combined to the bimonthly 48h leucovorin (LV) and 5-fluorouracil (5FU) regimens (FOLFOX) in metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 1999;18:246a.
25. Bécouarn Y, Rougier P. Clinical efficacy of oxaliplatin monotherapy : phase II trials in advanced colorectal cancer. Semin Oncol 1998;25 (Suppl 5) : 23-31.
26. Schmilovich A, Chacon R, Coppola F, Michiewicz E, Blajman C, Block J, et al. Expanded access program (EAP) single agent oxaliplatin (L-OHP) in fluoropyrimidine resistant advanced colorectal (FRAC) cancer patients (abstract). Proc Am Soc Clin Oncol 1998;17:272a.
27. Bertheault-Cvitkovic F, Jami A, Ithzaki M, Depres Brummer P, Brienza S, Adam R. et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1996;14:2950-8.
28. André T, Louvet C, Raymond E, Tournigand C, De Gramont A. Bimonthly high-dose leucovorin, 5-fluorouracil and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998;9:1251-3.
29. Garufi C, Bensmaine MA, Brienza S, Misset JL, Aschelter A, Pace R, et al. Addition of oxaliplatin (L-OHP®) to chronomodulated (CM) 5-fluorouracil (5-FU) and folinic acid (FA) for reversal of acquired chemoresistance in patients with advanced colorectal cancer (ACC). Eur J Cancer 1995;31 A (Suppl 5) : S29.
30. Extra JM, De Gramont A, Gamelin E, Bleiberg H, Francois E, André T, et al. Oxaliplatin (L-OHP) synergistic clinical activity with 5-fluorouracil (FU) in FU resistant colorectal cancer (CRC) patients (pts) is independent of the 5-FU administration modality and/or modulation by folinic acid (FA). Ann Oncol 1996;7 (Suppl 1) : 69.
31. Bensmaine MA, Marty M, De Gramont A, Misset JL, Cuvier C, Chollet P, et al. Extended Access French Programm (EAFP) of oxaliplatin (OXA) ± 5FU in 5-FU refractory advanced colorectal cancer (RACRC) patients (pts) (abstract). Proc Am Soc Clin Oncol 1999;18:253a.
32. De Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-9.
33. André T, Bensmaïne MA, Louvet C, Lucas V, Beerblock K, Desseigne F, et al. Addition of oxaliplatin (Eloxatine®) to the same leucovorin (LV) and 5-fluorouracil (5-FU) bimonthly regimens after progression in patients (pts) with metastatic colorectal cancer (MCRC) : preliminary report (abstract). Proc Am Soc Clin Oncol 1997;16:270a.
34. Meyer V, Delva R, Gamelin E, Lamezec B, Maillart P, Danquechin-Dorval E, et al. Oxaliplatin (LOHP) and 5-fluorouracil (5-FU) synergism in advanced colorectal cancer patients (ACRC). Eur J Cancer 1997;33 (Suppl8) : S167.
35. Giacchetti S, Brienza S, Focan C, Metouri A, Perpoint B, Faggiuolo R, et al. Contribution of second line oxaliplatin (OXA)-chronomodulated 5-fluorouracil-folinic acid (CM-5-FU-FA) and surgery to survival in metastatic colorectal cancer patients (MCC pts) (abstract). Proc Am Soc Clin Oncol 1998;17:273a.
36. Gérard B, Bleiberg H, Van Daele D, Gil T, Hendlisz A, Di Leo A, et al. Oxaliplatin combined to 5-fluorouracil and folinic acid : an effective therapy in patients with advanced colorectal cancer. Anti-Cancer Drugs 1998;9:301-5.
37. Maindrault-Goebel F, De Gramont A, Louvet C, André T, Carola E, Gilles-Amar V, et al. Bi-monthly oxaliplatin with leucovorin (LV) and 5-fluorouracil (5FU) in pretreated metastatic colorectal cancer (FOLFOX6) (abstract). Proc Am Soc Clin Oncol 1998;17: 273a.
38. Ducreux M, Rougier P, Polus M, Ould Kaci M, Ychou M, Conroy T. Résultats de l'association oxaliplatine-LV5FU2 toutes les 3 semaines dans les cancers colo-rectaux (CCR) avancés progressant sous 5-FU (résumé). Gastroenterol Clin Biol 1999;23 : A108.
39. Maindrault-Goebel F, De Gramont A, Louvet C, André T, Carola E, Gilles-Amar V, et al. High-dose oxaliplatin with the simplified 48h bimonthly leucovorin (LV) and 5-fluorouracil (5FU) regimen in pretreated metastatic colorectal cancer (FOLFOX) (abstract). Proc Am Soc Clin Oncol 1999;18:265a.
40. Giacchetti S, Zidani R, Perpoint B, Pinel MC, Faggiuolo R, Focan C, et al. Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC) (abstract). Proc Am Soc Clin Oncol 1997;16:229a.
41. De Gramont A, Figer A, Seymour M, Homerin M, Le Bail N, Cassidy J, et al. A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC) (abstract). Proc Am Soc Clin Oncol 1998;17:257a.
42. Seymour MT, Tabah-Fisch I, Homerin M. Quality of life (QoL) in advanced colorectal cancer (ACC) : a comparison of QoL during bolus plus infusion 5FU/leucovorin (LV5FU2) with or without oxaliplatin (abstract). Proc Am Soc Clin Oncol 1999;18:234a.
43. Bismuth H, Adam R. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol 1998;25 (Suppl5) : 40-6.
44. Seitz JF, Douillard JY, Paillot B, Gamelin E, Francois E, Conroy T, et al. "Tomudex" (raltitrexed) plus oxaliplatin as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients : a promising combination (abstract). Proc Am Soc Clin Oncol 1999;18:257a.
45. Wasserman E, Myara A, Lokiec F, Riofrio M, Bleuzen P, Santoni J, et al. Bilirubin (BIL) and SN-38 metabolism : pharmacodynamics of CPT-11 toxicity (abstract). Proc Am Soc Clin Oncol 1998;17:185a.
46. Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer : clinical efficacy and safety profile. Semin Oncol 1996;23 (Suppl 3) : 34-41.
47. Kosmidis P, Scarlos B, Georgoulias V, Panagos G, Fornasiero A, Di Costanzo F, et al. A randomized phase III multicentre trial of Campto (CPT-11) with or without lenograstim (Granocyte) support in 1st or 2nd line metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 1998;17:271a.
48. Droz JP, Marty M, Douillard JY, Ychou M, Rougier P, Bugat R, et al. CPT-11 in 5-FU resistant colorectal cancer : management of delayed diarrhoea. Ann Oncol 1996;7 (Suppl 5) : 48.
49. Bugat R, Adenis A, Dufour P, Audhuy B, Desseigne S, Raoul JL, et al. CPT-1 in 5-FU resistant colorectal cancer : effect of infusion duration on safety profile - preliminary data. Ann Oncol 1996;7 (Suppl 5) : 36.
50. Merrouche Y, Bugat R, Brunet R, Seitz JF, Lucas P, Conroy T, et al. High dose acetorphan (HDA) versus acetorphan + loperamide (A+L) in the treatment of CPT-11 induced (DD) diarrhea : preliminary report of a randomized phase II study in patients (pts) with advanced colorectal cancer (CRC) (abstract). Proc Am Soc Clin Oncol 1996;15:211.
51. Saltz LB, Locker PK, Pirotta N, Elfring GL, Miller LL, Weekly irinotecan (CPT-11), leucovorin (LV) and fluorouracil (FU) is superior to daily x 5 LV/FU in patients (pts) with previously untreated metastatic colorectal cancer (CRC) (abstract). Proc Am Soc Clin Oncol 1999;18:233a.
52. Rothenberg ML, Padzur R, Rowinsky EK, Cohn AL, Alberts DS, Petit RG, et al. A phase II multicenter trial of alternating cycles of irinotecan (CPT-11) and 5-FU/LV in patients with previously untreated metastatic colorectal cancer (CRC) (abstract). Proc Am Soc Clin Oncol 1997;16:266a.
53. Van Cutsem E, Pozzo C, Starkhammar H, Dirix L, Terzoli E, Cognetti F, et al. A phase II study of irinotecan alternated with five days bolus 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. Ann Oncol 1998;9:1119-204.
54. André T, De Gramont A, Louvet C, Carola E, Lotz JP, Maindrault-Goebel F, et al. Bi-monthly CPT11 with leucovorin (LV) and 5-fluorouracil (5FU) in pretreated metastatic colorectal cancer (FOLFIRI) (abstract). Proc Am Soc Clin Oncol 1998;17: 273a.
55. Seitz JF, Ducreux M, Ychou M, Bonnay M, Rougier P, Mignard D. et al. Phase I/II study of CPT-11 in combination with LV5FU2 (De Gramont-Regimen) every 2 weeks for the treatment of colorectal cancer (CRC) after 5-FU failure. Ann Oncol 1998; 9(Suppl 2) : 68.
56. Douillard JY, Cunningham D, Roth AD, Germa JR, James RD, Karasek P, et al. A randomized phase III trial comparing irinotecan (IRI) + 5-FU/folinic acid (FA) to the same schedule of 5-FU/FA in patients (pts) with metastatic colorectal cancer (MCRC) as front line chemotherapy (CT) (abstract). Proc Am Soc Clin Oncol 1999;18:233a.
57. Ychou M, Rougier P, Oberling F, Douillard JY, Extra JM, Adenis A, et al. A phase II randomized study of CPT-11 (Irinotecan) in colorectal cancer (CRC) refractory to 5-FU, with preventive treatment of delayed diarrhea using acetorphan (abstract). Proc Am Soc Clin Oncol 1996;15:212.
58. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, Punt CJA, Alexopoulos CG, Dirix L, et al. Clinical activity and benefit of irinotecan (CPT-11 ) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 1999;35:54-9.
59. Van Cutsem E, Rougier P, Droz JP, Marty M, Bleiberg H. Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer (CRC) resistant to 5-FU (abstract). Proc Am Soc Clin Oncol 1997;16:268a.
60. Hoeffken K, Ridwelsky C, Wein A, Mezger J, Stoffregen C, Weber B, et al. Phase II study of irinotecan as second line chemotherapy (CT) in metastatic colorectal cancer (CRC) (abstract). Proc Am Soc Clin Oncol 1998;18:244a.
61. Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TS, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352: 1413-8.
62. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-12.
63. Scheithauer W, Kornek GV, Raderer M, Valencak J, Weiländer G, Hejna M, et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol 1999;17:902-6.
64. Wagener TDJ, Verdonk HER, Dirix LY, Gatimel G, Siegenthaler P, Buitenhuis M, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995;6:129-32.
65. Sakata Y, Shimada Y, Yoshino M, Kambe M, Futatsuki K, Nakao I, et al. A late phase II study of CPT-11, Irinotecan hydrochloride, in patients with advanced pancreatic cancer. Jpn J Cancer Chemother 1994;21:1039-46.
66. Kohne CH, Thuss-Patience P, Catane R, Klein H, Peretz T, Preusser P, et al. Final results of a phase II trial of CPT-11 in patients with advanced gastric cancer (abstract). Proc Am Soc Clin Oncol 1999;18:258a.
67. Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997;15:921-7.
68. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-23.
69. O'Reilly E, Stuart K, Kemeny N, Steger C, Raeburn L, Sanz-Altamira P, et al. A phase II trial of irinotecan (CPT-11) in patients with advanced hepatocellular carcinomas (HCC) (abstract). Proc Am Soc Clin Oncol 1998;17:267a.
70. Enzinger PC, Ilson DH, Saltz LB, O'Reilly EM, Gollub MJ, Degroff JA, et al. A phase II trial of cisplatin and irinotecan in patients with advanced esophageal cancer (abstract). Proc Am Soc Clin Oncol 1998;17:282a.
71. Saltz L, Kemeny NE, Tong W, Harrison J, Berkery R, Kelsen DP. 9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil refractory colorectal carcinoma. Cancer 1997;80:1727-32.
72. Wanders J, Ten Bokkel Huinink WW, Heinrich B, Gore M, Calvert AH, Lehnert M, et al. Phase II studies with GI-147211 in 5 different tumor types - preliminary results. Ann Oncol 1996;7 (Suppl 5) : 131.
73. Creemers GJ. Topotecan in advanced colorectal cancer. Semin Oncol 1997;24 (Suppl 20) : 42-8.
74. Benedetti JK, Burris HA, Balcerzak SP, Macdonald JS. Phase II trial of topotecan in advanced gastric cancer : a Southwest Oncology Group study. Invest New Drugs 1997;15:261-4.
75. Saltz LB, Schwartz GK, Ilson DH, Quan V, Kelsen DP. A phase II study of topotecan administered five times daily in patients with advanced gastric cancer. Am J Clin Oncol 1997;20:621-5.
76. Scher RM, Kosierowski R, Lusch C, Alexander R, Fox S, Redei I, et al. Phase II trial of Topotecan in advanced or metastatic adenocarcinoma of pancreas. Invest New Drugs 1995;13:347-54.
77. O'Reilly S, Donehower RC, Rominsky EK, Ord S, Grochow LB. A phase II trial of Topotecan in patients with previously untreated pancreatic cancer. Anti-Cancer Drugs 1996;7:410-4.
78. Ron IG, Lotan A, Inbar MJ, Chaitchik S. Advanced colorectal carcinoma : redefining the role of oral ftorafur. Anti-Cancer Drugs 1996;7:649-54.
79. Isla MD, Mayordomo JI, Cajal R, Saenz A, Escudero P, Tres A. Oral tegafur and folinic acid for the treatment of advanced colorectal cancer. Eur J Cancer 1997;33:166-7.
80. Cirera L, Balil A, Batiste E, Tusquets I, Cardona T, Arcusa A, et al. Efficacy of adjuvant mitomycin C plus tegafur in stage II gastric cancer (abstract). Proc Am Soc Clin Oncol 1997;16:278a.
81. Grau JJ, Estape J, Fuster J, Filella X, Visa J, Teres J, et al. Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. J Clin Oncol 1998;16:1036-9.
82. Nakazato H, Koike A, Sail S, Suzuki H, Takagi H, Nimura Y, et al. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer : a prospective randomized clinical trial (abstract). Proc Am Soc Clin Oncol 1997;16:279a.
83. Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma : a comprehensive review. J Clin Oncol 1998;16:2877-85.
84. Ravaud A, Borner M, Schellens JHM, Geoffrois L, Schöffski P, Wanders J, et al. Phase II with UFT + folinic acid (FA) in patients with metastatic gastric cancer. Ann Oncol 1998;9 (Suppl 2) : 163.
85. Pazdur R. Phase II study of UFT® plus leucovorin in colorectal cancer. Oncol 1997;54 (Suppl 1) : 19-23.
86. Feliu J, Gonzalez Baron M, Espinosa E, Garcia Giron C, De La Gandara I, Espinosa J, et al. Uracil and tegafur modulated with leucovorin. An effective regimen with low loxicity for the treatment of colorectal carcinoma in the elderly. Cancer 1997;79: 1884-9.
87. Sulkes A, Benner SE, Canetta RM. Uracil-Ftorafur : an oral fluoropyrimidine active in colorectal cancer. J Clin Oncol 1998;16:3461-75.
88. Padzur R, Douillard JY, Skillings JR. Eisenberg PD, Davidson N, Harper P, et al. Multicenter phase III study of 5-fluorouracil (5-FU) ou UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 1999;18:263a.
89. Carmichael J, Popiela T, Radstone D, Falk S, Fey M, Oza A, et al. Randomized comparative study of Orzel® (Oral Uracil/Tegafur (UFT™) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 1999;18:264a.
90. Mani S, Kugler J, Sciortino D, Garcia J, Ansari R, Tembe S, et al. A phase II trial of UFT with leucovorin for the treatment of advanced pancreatic, hepatocellular and biliary cancer : a University of Chicago phase II Consortium study. Ann Oncol 1998;9 (Suppl 2) : 163.
91. Horikoshi N, Mitachi Y, Sakata Y, Sugimachi K, Taguchi T for S-1 Cooperative Study Group. S-1, new oral fluoropyrimidine is very active in patients with advanced gastric cancer (early phase II study) (abstract). Proc Am Soc Clin Oncol 1996;15:206.
92. Kurihara M, Koizumi W, Hasegawa K, Nakano S for the S-1 Cooperative Study K-Group. Late phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with advanced gastric cancer (abstract). Proc Am Soc Clin Oncol 1998;17:262a.
93. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1(1 M Tegafur-0.4 M Gimestat-1 M Otastat Potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
94. Baba H, Ohtsu A, Sakata Y, Mitachi Y, Sugimachi K, Taguchi T. Late phase II study of S-1 in patients with advanced colorectal cancer in Japan (abstract). Proc Am Soc Clin Oncol 1998;18:277a.
95. Bajetta E, Di Bartolomeo M, Somma L, Moreschi M, Comella G, Turci D, et al. Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma. Cancer 1996;78: 2087-93.
96. Falcone A, Pfanner E, Ricci S, Bertuccelli M, Cianci C, Carrai M, et al. Oral doxifluridine in elderly patients with metastatic colorectal cancer. A multicenter phase-II study. Ann Oncol 1994;5:760-2.
97. Bajetta E, Colleoni M, Di Bartolomeo M, Buzzoni R, Bozzetti F, Doci R, et al. Doxifluridine and leucovorin : an oral treatment combination in advanced colorectal cancer. J Clin Oncol 1995;13:2613-9.
98. Di Bartolomeo M, Bajetta E, Somma L, Leo A, Del Vecchio M, Pandolfi A. Oral doxifluridine and low-dose leucovorin in gastrointestinal tumors (abstract). In : Abstract book of the Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Köln, 1995;126.
99. Takiguchi N, Nakajima N, Saitoh N, Fujimoto S, Nakazato H. A phase III study comparing oral 5′-deoxy-5-fluorouridine and oral 5-fluorouracil in patients with curative gastric cancer (abstract). Proc Am Soc Clin Oncol 1999;18:244a.
100. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58:685-90.
101. Reigner B, Verweij J, Dirix L, Cassidyl, Twelves C, Allman D, et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 1998;4:941-8.
102. Schüller J, Cassidy J, Reigner BG, Durston S, Roos B, Ishitsuka H, et al. Tumor selectivity of Xeloda™ in colorectal cancer patients (abstract). Proc Am Soc Clin Oncol 1997;16:227a.
103. Findlay M, Van Cutsem E, Kocha W, Allman D, Laffranchi B, Griffin T, et al. A randomized phase II study of Xeloda™ (capecitabine) in patients with advanced colorectal cancer (abstract). Proc Am Soc Clin Oncol 1997;16:227a.
104. Twelves C, Harper P, Van Cutsem E, Thibault A, Shelygin YA, Burger HY, et al. A phase III trial (S014796) of Xeloda™ (capecitabine) in previously untreated advanced/metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 1999;18:263a.
105. Cox JV, Pazdur R, Thibault A, Maroun J, Weaver C, Jahn MW, et al. A phase III trial of Xeloda® (capecitabine) in previously untreated advanced/metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 1999;18:265a.
106. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
107. Carmichael J, Fink U, Russell RCG, Spittle MF, Harris AL, Spiessi G, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73:101-5.
108. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-53.
109. Niyikiza C, Andersen JS, Tarassoff PG, Rothenberg ML, Seitz DE, Nelson RL, et al. Prognostic factors in a randomized trial of gemcitabine (GEM) versus 5-FU as first-line therapy in advanced pancreatic cancer and in pancreatic cancer patients failing 5-FU who receive gemcitabine (GEM) as a palliative therapy (abstract). Proc Am Soc Clin Oncol 1996;15:506.
110. Burris AH, Moore MJ, Andersen J, Green Mr, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 1997;15:2403-13.
111. Caraceni A, De Conno F. Analgesic effects of chemotherapy ? J Clin Oncol 1998;16:803.
112. Ballatori E, Del Favero A, Roila F. Clinical benefit as a primary efficacy endpoint. J Clin Oncol 1998;16:803-4.
113. Heinemann V, Wilke H, Possinger K, Mergenthaler K, Clemens M, König HJ, et al. Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer. Final results of a phase II study (abstract). Proc Am Soc Clin Oncol 1999;18:274a.
114. Colucci G, Riccardi F, Giuliani F, Lopez M, Gebbia V, Uomo G, et al. Randomized trial of gemcitabine (GEM) alone or with cisplatin (CDDP) in the treatment of advanced pancreatic cancer (APC) : a phase II multicenter study of the Southern Italy Oncology Group (abstract). Proc Am Soc Clin Oncol 1999;18: 250a.
115. Philip PA, Zalupski M, Vaitkevicius VK, Arlauskas P, Shields A. Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer (abstract). Proc Am Soc Clin Oncol 1999;18:274a.
116. Cascinu S, Silva RR, Barni S, Labianca R, Frontini L, Pancera G, et al. Gemcitabine (GEM) and 5-fluorouracil (5-FU) in advanced pancreatic cancer : a GISCAD phase II study (abstract). Proc Am Soc Clin Oncol 1998;17:264a.
117. Louvet C, Hammel P, André T, Vanica R, Landi B, Balosso J, et al. Multicenter phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of leucovorin, 5FU bolus and infusion, and gemcitabine (FOLFUGEM regimen) (abstract). Proc Am Soc Clin Oncol 1999;18:275a.
118. Mani S, Knost J, Gibbons J, Garcia J, Sciortino D, Taber D, et al. Phase II trial of prolonged infusion gemcitabine (Gemzar) in advanced colorectal carcinoma : in vivo proof of a pharmacologic principle. Ann Oncol 1998;9 (Suppl 2) : 156.
119. Sessa C, Aamdal S, Wolff I, Eppelbaum R, Smyth JF, Sulkes A, et al. Gemcitabine in patients with advanced malignant melanoma or gastric cancer : phase II studies of the EORTC Early Clinical Trials Group. Ann Oncol 1994;5:471-2.
120. Christman K, Kelsen D, Saltz L, Tarassoff PG. Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer 1994;73:5-7.
121. Gebbia V, Maiello E, Testa A, Cannata G, Colucci G, Gebbia N. Single agent vinorelbine in the treatment of unresectable lung metastases from colorectal cancer. Oncol Rep 1996;3:563-5.
122. Etienne PL, Douillard JY, Adenis A, Bretagne JF. A phase II study of vinorelbine in metastatic pancreatic adenocarcinoma. Eur J Cancer 1993;29A (Suppl 6) : S105.
123. Conroy T, Etienne PL, Adenis A, Wagener TDJ, Paillot B, Francois E, et al. Phase II trial of Vinorelbine in metastatic squamous cell esophageal carcinoma. J Clin Oncol 1996;14:164-70.
124. Etienne PL, Conroy T, Adenis A, Ducreux M, Oliveira J, Paillot B, et al. Vinorelbine and cisplatin in metastatic epidermoid carcinoma of the esophagus (MECE). An EORTC phase II study (abstract). Proc Am Soc Clin Oncol 1999;18:270a.
125. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086-91.
126. Kok TC, Van Der Gaast A, Kerkhofs L, Splinter TAW. Biweekly administration of cisplatin and increasing doses of paclitaxel in patients with advanced esophageal cancer (abstract). Proc Am Soc Clin Oncol 1998;17:260a.
127. Costa F, Ilson DH, Forastiere A, Patel P, Heelan R, Huang Y. et al. Phase II study of paclitaxel and cisplatin in patients with advanced adenocarcinoma (A) and squamous cell (S) carcinoma of the esophagus (abstract). Proc Am Soc Clin Oncol 1997;16:262a.
128. Kelsen D, Ginsberg R, Bains M, Cooper J, Arquette M, Forastiere AA, et al. A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer. Semin Oncol 1997;24 (Suppl 19) : 77-81.
129. Ilson D, Arquette M, Costa F, Bains M, Patel P, Huang Y, et al. Preoperative paclitaxel/cisplatin in esophageal carcinoma : a phase II multicenter trial (abstract). Proc Am Soc Clin Oncol 1997;16:261a.
130. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998;16:1826-34.
131. Einzig AI, Lipsitz SR, Wiernik PH, Benson AB. Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The eastern cooperative oncology group (ECOG) results. Invest New Drugs 1995;13:223-7.
132. Murad AM, Tinoco LA, Guimaraes RC, Procopio R, Aragao BC, Ferreira-Filho AF, et al. Paclitaxel (T) plus 5-fluorouracil (5-FU) : a novel and very active regimen for advanced gastric cancer (AGC). A phase II trial (abstract). Proc Am Soc Clin Oncol 1997;16:298a.
133. Kim JS, Shin SW, Kim BS, Kim JH, Mok YJ, Kim JS, et al. A phase II trial of Taxol® (TAX), cisplatin (CDDP), and 5-fluorouracil (FU) in patients with advanced gastric carcinomas (AGC) (abstract). Proc Am Soc Clin Oncol 1997;16:293a.
134. Bokemeyer C, Hartmann JT, Lampe CS, Clemens MR, Quietzsch D, Forkmann L, et al. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Semin Oncol 1997;24 (Suppl 19) : 96-100.
135. Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, Macdonald JS. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma : a Southwest Oncology Group Study. J Clin Oncol 1997;15:2414-9.
136. Safran H, King TP, Choy H, Hesketh PJ, Wolf B, Altenhein E, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer : a phase I study. J Clin Oncol 1997;15:901-7.
137. Jones DV, Lozano R, Hoque A, Markowitz A, Patt, YZ. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996;14:2306-10.
138. Chao Y, Chan W-K, Birkhofer MJ, Hu OY-P, Wand S-S, Huang Y-S, et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 1998;78:34-9.
139. Vaughn DJ, Shaw LM, Recio A, Bonner H, Haller DG. A phase II trial of 96-hour infusional paclitaxel with pharmacokinetic analysis in metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 1995;14:213.
140. Tanaka M, Obata T, Sasaki T. Evaluation of antitumor effects of Docetaxel (Taxotere®) on human gastric cancers in vitro and in vivo. Eur J Cancer 1996:32A : 226-30.
141. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, et al. Docetaxel (Taxotere®) in advanced gastric cancer : results of a phase II clinical trial. Br J Cancer 1994;70:380-3.
142. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, et al. Phase II trial of docetaxel (Taxoterel in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy : the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996;13:87-93.
143. Taguchi T. A late phase II study of docetaxel in patients with gastric cancer (abstract). Proc Am Soc Clin Oncol 1997;16:263a.
144. Mavroudis D, Kakolyris S, Kouroussis C, Androulakis N, Agelaki S, Kalbakis K, et al. First line treatment of advanced gastric cancer with docetaxel monotherapy and granulocyte colony-stimulating factor (G-CSF) (abstract). Proc Am Soc Clin Oncol 1999:18:254a.
145. Wilke H, Vanhoefer U, Harstrick A, Achterrath W, Preusser PW, Clemens MR, et al. Phase II study of docetaxel as salvage chemotherapy in patients with advanced gastric cancer (abstract). Proc Am Soc Clin Oncol 1998;17:305a.
146. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, et al. Taxotere-Cisplatin (TC) in advanced gastric carcinoma (AGC) : an active drug combination (abstract). Proc Am Soc Clin Oncol 1998;17:283a.
147. Rougier P, Adenis A, Ducreux M, Djazouli K, De Forni M, Adams D, el al. Phase II study of Docetaxel (Taxotere®) in pancreatic adenocarcinoma (PAC) : final results after extra-mural review (abstract). In : Abstract book of the Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies. Köln, 1995;126.
148. Androulakis N, Kourousis C, Dimopoulos MA, Samelis G, Kakolyris S, Tsavaris N, et al. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor : a multicenter phase II study. J Clin Oncol 1999;17:1779-85.
149. Okada S, Taguchi T. Phase II trial of docetaxel (taxotere) as first-line chemotherapy in patients with metastatic pancreatic cancer : a Japanese cooperative study (abstract). Proc Am Soc Clin Oncol 1998;17:265a.
150. Royce M, Pazdur R, Rodriguez GM, Rinaldi DA, Patt YZ, Burris HA. Phase II study of docetaxel in patients with unresectable cholangiocarcinoma. Ann Oncol 1998;9 (Suppl 2) : 99.
151. Padzur R, Lassere Y, Soh LT, Ajani JA, Bready B, Soo E, et al. Phase II trial of docetaxel (Taxotere®) in metastatic colorectal carcinoma. Ann Oncol 1994;5:468-70.
152. Sternberg CN, Ten Bokkel Huinink WW, Smyth JF, Bruntsch V, Dirix LY, Pavlidis NA, et al. Docetaxel (Taxotere®), a novel taxoid, in the treatment of advanced colorectal carcinoma : an EORTC Early Clinical Trials Group Study. Br J Cancer 1994;70:376-9.